Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by SPCEO1on Jul 15, 2021 8:34am
325 Views
Post# 33548162

Pretty close to an ideal situation

Pretty close to an ideal situation1.) The phase I cancer trial is going according to plan and will report in Q4. That means to me that they are not seeing toxicity issues and they will be able to give the maximum dose. If so, the chances for significant efficacy results jump considerably.

2.) The partnerring of the NASH trial tells us again that the cancer trial is looking very good. The protocol includes a mid trial look to see if it should continue. Partnerring it may not be easy and they are losing time to competitors, but NASH may drift off the radar screen entirely if the cancer results are good.

3.) Legacy drug sales were as expected. So, at elast no harm was done on that front.

4.) Great expense control and cash management. 


<< Previous
Bullboard Posts
Next >>